Boehringer

Encephalomyelitis-Rhinopneumonitis-Influenza Vaccine

Eastern & Western, Killed Virus

Tetanus Toxoid

Indications: For vaccination of healthy horses 4 months of age or older as an aid in the prevention of disease caused by Eastern and Western Encephalomyelitis, tetanus, and as an aid in reduction of respiratory diseases caused by Equine Herpesvirus types 1 and 4 (EHV-1 and EHV-4); and as an aid in the reduction of respiratory disease and shedding caused by A2 Equine Influenza virus. Product contains Kentucky Lineage (KY/95), Florida sublineage clade 1 (OH/03), and Florida sublineage clade 2 (RI/07) equine influenza strains. Efficacy (DOI) has been demonstrated for at least 6 months against OH/03.

Administration and dosage: Shake well before use. Using aseptic technique, inoculate horses intramuscularly with a 1 mL dose. Administer a second 1 mL dose intramuscularly in 3-4 weeks using a different injection site. Revaccinate annually and prior to anticipated exposure with a single 1 mL intramuscular dose.

Precautions: Store at 35 - 45°F (2 - 7°C). Protect from freezing. Do not vaccinate within 21 days before slaughter. Anaphylactoid reactions may occur following use. Antidote: Epinephrine.

This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy in normal, healthy, immunocompetent animals. This level of performance may be affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies, or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.

Preservatives: Gentamicin and Amphotericin B.

For Veterinary Use Only

Vetera^® is a registered trademark of Boehringer Ingelheim Vetmedica GMBH.

© 2013 Boehringer Ingelheim Vetmedica, Inc. All Rights Reserved.

Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506

US Vet. Lic. No. 124

US Patent No. 7572620. Used under license.